ReviewAmerican journal of physiology. Regulatory, integrative and comparative physiology2015
Principles of the prolactin/vasoinhibin axis.
Review in American journal of physiology. Regulatory, integrative and comparative physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial.Eye (London, England) · 2024Trial
- Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy.Translational vision science & technology · 2020Trial
- Article
- Prolactin as a Candidate Biomarker in Non-Small Cell Lung Cancer: Implications for Personalized Medicine and Post-Treatment Risk Stratification.Journal of personalized medicine · 2026Review
- The spectrum of pregnancy-induced cardiac remodeling: transitioning from healthy adaptive hypertrophy to peripartum cardiomyopathy.Frontiers in cell and developmental biology · 2026Review
- Cardiovascular Safety of VIAN-c4551, an Antiangiogenic Peptide Derived From Vasoinhibin.Drug development research · 2025Article
- The Interplay of Prolactin with Inflammatory Nutritional Markers and NT-proBNP in Chronic Kidney Disease.International journal of molecular sciences · 2025Observational
- Vasoinhibin is Generated by the Renin-angiotensin System.Endocrinology · 2025Article
- Mildly elevated serum prolactin level may be a protective factor for preventing thickening of the carotid intima-media in patients with type 2 diabetes mellitus.Endocrine connections · 2025Article
- Retinal prolactin isoform PRLΔE1 sustains rod disease in inherited retinal degenerations.Cell death & disease · 2024Article
- Immunometric and functional measurement of endogenous vasoinhibin in human sera.Frontiers in endocrinology · 2024Article
- Vasoinhibin's Apoptotic, Inflammatory, and Fibrinolytic Actions Are in a Motif Different From Its Antiangiogenic HGR Motif.Endocrinology · 2023Article
- The role of prolactin/vasoinhibins in cardiovascular diseases.Animal models and experimental medicine · 2023Review
- The significance of prolactin in systemic connective tissue diseases.Reumatologia · 2023Review
- Birth, love, and fear: Physiological networks from pregnancy to parenthood.Comprehensive psychoneuroendocrinology · 2022Review
- The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide.Angiogenesis · 2022Article
- Dual Roles of Prolactin and Vasoinhibin in Inflammatory Arthritis.Frontiers in endocrinology · 2022Review
- Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited.Frontiers in endocrinology · 2022Review
- Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis.Cells · 2021Review
- Short prolactin isoforms are expressed in photoreceptors of canine retinas undergoing retinal degeneration.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hormonal family of vasoinhibins, which derive from the anterior pituitary hormone prolactin, are known for their inhibiting effects on blood vessel growth, vasopermeability, and vasodilation. As pleiotropic hormones, vasoinhibins act in multiple target organs and tissues. The generation, secretion, and regulation of vasoinhibins are embedded into the organizational principle of an axis, which integrates the hypothalamus, the pituitary, and the target tissue microenvironment. This axis is designated as the prolactin/vasoinhibin axis. Disturbances of the prolactin/vasoinhibin axis are associated with the pathogenesis of retinal and cardiac diseases and with diseases occurring during pregnancy. New phylogenetical, physiological, and clinical implications are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.